## Accepted Manuscript

Vitamin D and kidney disease



Farzana Perwad, Lisa Keung

PII: S2352-1872(18)30043-3

DOI: doi:10.1016/j.bonr.2018.07.002

Reference: BONR 173

To appear in: Bone Reports

Received date: 2 November 2017

Revised date: 25 June 2018 Accepted date: 2 July 2018

Please cite this article as: Farzana Perwad, Lisa Keung, Vitamin D and kidney disease. Bonr (2018), doi:10.1016/j.bonr.2018.07.002

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **ACCEPTED MANUSCRIPT**

1. Title – Vitamin D and Kidney Disease

Farzana Perwad

University of California San Francisco, San Francisco, California UNITED STATES

Lisa Keung

MS, RD, CSP, University of California San Francisco

- 2. **Key Words** calcium, vitamin D, parathyroid hormone (PTH), parathyroid hormone related protein (PTHrP), kidney
- 3. Abstract

Calcium and phosphorus are essential minerals required for many critical biologic functions including cell signaling, energy metabolism, skeletal growth and integrity. Calcium and phosphate homeostasis are maintained primarily by regulation of epithelial calcium and phosphate cotransport in the kidney and intestine, processes that are tightly regulated by hormones including 1,25 dihydroxyvitamin D (1,25(OH)<sub>2</sub>D), fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH). In patients with chronic kidney disease (CKD), as renal function declines, disruption of feedback loops between these hormones have adverse consequences on several organ systems, including the skeleton, heart and vascular system. CKD-associated mineral and bone disorder (CKD-MBD) is defined as a systemic disorder of mineral and bone metabolism due to CKD manifested by abnormalities of calcium, phosphorus, PTH or vitamin D metabolism, abnormalities of bone turnover, mineralization and volume, and ectopic soft tissue calcification. Complications of CKD-MBD include vascular calcification, stroke, skeletal fracture and increased risk of death. Increased FGF23 and PTH concentrations, and 1,25(OH)<sub>2</sub>D deficiency contribute to the pathogenesis of CKD-MBD. Therefore, treatment of patients with CKD-MBD is focused on restoring the feedback loops to maintain normal calcium and phosphate balance to prevent skeletal and cardiovascular complications.

## Download English Version:

## https://daneshyari.com/en/article/8627542

Download Persian Version:

https://daneshyari.com/article/8627542

<u>Daneshyari.com</u>